Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Inflammatory Pathways
100%
Randomized Clinical Trial
100%
Urban children
100%
Asthma Exacerbation
100%
Mepolizumab
100%
Placebo
57%
Type 2 Inflammation
42%
Molecular Mechanism
28%
Macrophages
28%
Illness
28%
False Discovery Rate
28%
Acute Exacerbation
28%
Acute Respiratory Distress Syndrome
28%
Respiratory Illness
28%
RNA Sequencing (RNA-seq)
14%
Clinical Outcomes
14%
Placebo-controlled
14%
Clinical Trials
14%
Gene Expression
14%
Trial Registration
14%
Eosinophils
14%
Epithelium
14%
Decreased Expression
14%
High-level Expression
14%
Upper Airway
14%
Pulmonary Function
14%
Children with Asthma
14%
Transcriptomics
14%
Low-income
14%
Respiratory Viruses
14%
Immune Therapy
14%
Group Randomized
14%
Transcriptional Signature
14%
Systems Approach
14%
Acute Asthma Exacerbation
14%
Inflammatory Macrophages
14%
Cellular Stress Response
14%
Stress Response Pathway
14%
Subcutaneous Injection
14%
Biologic Therapy
14%
Multiple Alternatives
14%
Mucus Secretion
14%
Gene Module
14%
Eosinophilic Asthma
14%
Nasal Samples
14%
Mucus Hypersecretion
14%
Urban Centers
14%
Exacerbation Rate
14%
US Cities
14%
Primary Measurement
14%
Viral Exacerbation
14%
Modular Analysis
14%
Approach Phase
14%
Semi-orthogonal
14%
Secretion Stress
14%
Medicine and Dentistry
Asthma Exacerbation
100%
Mepolizumab
100%
Randomized Clinical Trials
100%
Placebo
71%
Respiratory Disease
57%
Macrophage
42%
Asthma
42%
Diseases
28%
RNA Sequence
14%
Clinical Trial
14%
Upregulation
14%
Eosinophilic
14%
Mucus Secretion
14%
Mucus
14%
Lung Function
14%
Transcriptomics
14%
Cellular Stress Response
14%
Subcutaneous Injection
14%
Biological Therapy
14%
Virus
14%
Eosinophil
14%
Pharmacology, Toxicology and Pharmaceutical Science
Asthma
100%
Randomized Clinical Trial
100%
Mepolizumab
100%
Placebo
62%
Respiratory Tract Disease
50%
Inflammation
37%
Diseases
25%
Clinical Trial
12%
Biological Product
12%
Respiratory Virus
12%
RNA-Sequencing
12%
Subcutaneous Injection
12%
Immunology and Microbiology
Asthma Exacerbation
100%
Mepolizumab
100%
Asthma
42%
Macrophage
42%
Biological Product
14%
RNA Sequence
14%
Cellular Stress Response
14%
Upregulation
14%
Lung Function
14%
Respiratory Virus
14%
Eosinophil
14%
Transcriptomics
14%
Mucus Secretion
14%
Airway
14%
Biochemistry, Genetics and Molecular Biology
Randomized Clinical Trial
100%
Mepolizumab
100%
Macrophage
42%
Upregulation
14%
RNA Sequence
14%
Clinical Trial
14%
Cellular Stress Response
14%
Transcriptomics
14%
Lung Function
14%
Mucus Secretion
14%
Respiratory Virus
14%